Acute Bacterial Skin and Skin Structure Infections Market, by Drug Type (Oral & Parenteral Antibiotics {Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others (Rifampin, Doxycycline, Minocycline, and Trimethoprim-S

Acute Bacterial Skin and Skin Structure Infections Market, by Drug Type (Oral & Parenteral Antibiotics {Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others (Rifampin, Doxycycline, Minocycline, and Trimethoprim-Sulfa Methoxazol, among others)}, and Topical Antibiotics {Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine}), by Infection Type (Hospital Acquired ABSSSI, and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Acute bacterial skin and skin structure infections (ABSSSI) are the type of skin and soft tissue infections that affect the epidermis, dermis, and subcutaneous tissues. The U.S. Food and Drug Administration (US FDA) defines ABSSSI as lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2. Pathogens such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, and Pseudomonas aeruginosa are the major causes of ABSSSI. This infection is difficult to treat due to increasing prevalence of drug resistant strains, especially in Staphylococcus spp. and Enterococcus spp.

Market Dynamics

Increasing incidence of ABSSSI, rising research and development activities by market players, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global acute bacterial skin and skin structure infections (ABSSSI) market over the forecast period.

For instance, in July 2020, Sandoz Inc., a Switzerland based pharmaceutical company (a Novartis Division) announced the launch of Daptomycin for injection 500 mg, an AP-rated generic version of Cubicin (daptomycin) in the U.S., for treatment of adult patients with complicated skin and skin structure infections (cSSSI) (also known as ABSSSI) caused by Gram-positive bacteria and certain bloodstream infections such as right-sided infective endocarditis, and others

Key features of the study:

• This report provides an in-depth analysis of the global acute bacterial skin and skin structure infections (ABSSSI) market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global acute bacterial skin and skin structure infections (ABSSSI) market based on the following parameters – company overview, financial performance, Material portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Arrevus, Inc., AbbVie, Inc., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Accord Healthcare Ltd., Intas Pharmaceuticals Ltd., Fresenius SE & Co. KGaA, Sandoz Inc., Glenmark Pharmaceuticals Ltd, and Cadila Healthcare Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future Material launches, type up-gradation, market expansion, and marketing tactics
• The global acute bacterial skin and skin structure infections (ABSSSI) market report caters to various stakeholders in this industry including investors, suppliers, material manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute bacterial skin and skin structure infections (ABSSSI) market

Detailed Segmentation:

• Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Drug Type:
• Oral & Parenteral Antibiotics
• Vancomycin
• Linezolid
• Clindamycin
• Ceftaroline
• Daptomycin
• Dalbavancin
• Tedizolid
• Others (Rifampin, Doxycycline, Minocycline, and Trimethoprim-Sulfa Methoxazol, among others)
• Topical Antibiotics
• Hydrogen Peroxide
• Fusidic Acid
• Mupirocin
• Retapamulin
• Povidone-Iodine
• Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Infection Type:
• Hospital Acquired ABSSSI
• Community Acquired ABSSSI
• Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Route of Administration:
• Oral
• Parenteral
• Topical
• Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Merck & Co., Inc.*
• Company Overview
• Material Portfolio
• Financial Performance
• Key Highlights
• Market Strategies
• Pfizer, Inc.
• GlaxoSmithKline plc.
• Teva Pharmaceutical Industries Ltd.
• Paratek Pharmaceuticals, Inc.
• Melinta Therapeutics, Inc.
• Arrevus, Inc.
• AbbVie, Inc.
• Aurobindo Pharma Ltd.
• Amneal Pharmaceuticals LLC
• Sun Pharmaceutical Industries Ltd.
• Accord Healthcare Ltd.
• Intas Pharmaceuticals Ltd.
• Fresenius SE & Co. KGaA
• Sandoz Inc.
• Glenmark Pharmaceuticals Ltd
• Cadila Healthcare Ltd.

“*” marked represents similar segmentation in other categories in the respective section.